Literature DB >> 30585633

Apelin/APJ system: A potential therapeutic target for endothelial dysfunction-related diseases.

Jun Cheng1, Xuling Luo1, Zhen Huang1,2, Linxi Chen1.   

Abstract

APJ is a G protein-coupled receptor and its endogenous ligand is apelin. Studies have shown that apelin/APJ system is widely distributed in the body, especially highly expressed in the vascular endothelial cells (ECs). Numerous reports have demonstrated that apelin/APJ system plays an important role in the regulation of ECs function. Our lab has demonstrated that apelin-13 is able to promote adhesion of monocyte-human umbilical vein EC via 14-3-3, and reactive oxygen species-autophagy signaling pathways. In this review, we concentrate on the regulatory mechanism of apelin/APJ system in EC, including promotion of proliferation, migration, and angiogenesis. Moreover, we also analyze the role of apelin/APJ on endothelial dysfunction-related diseases including atherosclerosis, diabetes, hypertension, and myocardial infarction. Finally, we summarize the most commonly used agonists and antagonists of APJ. Therefore, apelin/APJ system is expected to be a therapeutic target for the treatment of endothelial dysfunction-related diseases.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  agonists; antagonists; apelin; endothelial cells

Mesh:

Substances:

Year:  2018        PMID: 30585633     DOI: 10.1002/jcp.27942

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

Review 1.  Progress of Adipokines in the Female Reproductive System: A Focus on Polycystic Ovary Syndrome.

Authors:  Peipei Chen; Rui Jia; Yuanyuan Liu; Mingya Cao; Liang Zhou; Zhiming Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-26       Impact factor: 6.055

Review 2.  Vascular homeostasis at high-altitude: role of genetic variants and transcription factors.

Authors:  Neha Chanana; Tsering Palmo; John H Newman; M A Qadar Pasha
Journal:  Pulm Circ       Date:  2020-11-19       Impact factor: 3.017

3.  Effect and Mechanism of Si-Miao-Yong-An on Vasa Vasorum Remodeling in ApoE-/- Mice with Atherosclerosis Vulnerable Plague.

Authors:  Meng Li; Zhongwen Qi; Junping Zhang; Ke Zhu; Yueyao Wang
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

4.  Correlation Between Apelin and Collateral Circulation in Patients with Middle Cerebral Artery Occlusion and Moyamoya Disease.

Authors:  Hanlin Wu; Chengyu Xia; Rui Li; Chunrong Tao; Qiqiang Tang; Wei Hu
Journal:  Int J Gen Med       Date:  2022-01-19

Review 5.  Research Progress on Mechanism of Neuroprotective Roles of Apelin-13 in Prevention and Treatment of Alzheimer's Disease.

Authors:  Teng Wan; Mingyuan Fu; Yan Jiang; Weiwei Jiang; Peiling Li; Shouhong Zhou
Journal:  Neurochem Res       Date:  2021-09-13       Impact factor: 3.996

Review 6.  Recent advances in molecular biology of metabolic syndrome pathophysiology: endothelial dysfunction as a potential therapeutic target.

Authors:  Basheer Abdullah Marzoog
Journal:  J Diabetes Metab Disord       Date:  2022-08-31

Review 7.  International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Authors:  Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

8.  Apelin‑36 protects against lipopolysaccharide‑induced acute lung injury by inhibiting the ASK1/MAPK signaling pathway.

Authors:  Qiong He; Yuqiao Wang; Hua Yang; Jianmin Wang; Jia Zhang; Danni Liu
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

9.  Prolyl Carboxypeptidase Mediates the C-Terminal Cleavage of (Pyr)-Apelin-13 in Human Umbilical Vein and Aortic Endothelial Cells.

Authors:  Emilie De Hert; An Bracke; Isabel Pintelon; Eline Janssens; Anne-Marie Lambeir; Pieter Van Der Veken; Ingrid De Meester
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.